Skip to main content
. 2007 Nov 19;111(4):2238–2245. doi: 10.1182/blood-2007-06-097253

Figure 6.

Figure 6

HMC1.1 cells are sensitive to inhibitors targeting JAK1, JAK3, and SRC. (A) HMC1.1 and K562 control cells were treated with increasing concentrations of the SRC family inhibitor, PP2. 72 hours later, cells were subjected to an MTS assay for determination of total viable cells. Values represent mean plus or minus SEM. (n = 3). (B) HMC1.1 and K562 control cells were treated with increasing concentrations of the pan-JAK inhibitor, JAK inhibitor I, alone or in combination with 1.5 μM PP2. 72 hours later, cells were subjected to an MTS assay for determination of total viable cells. Values represent mean plus or minus SEM. (n = 3).